The role of dopamine in the pathophysiology of depression

Archives of General Psychiatry

Volumn 64, Issue 3, 2007, Pages 327-337

  Dunlop, Boadie W ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; PAROXETINE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL; DEPRESSION; DNA POLYMORPHISM; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; HUMAN; NEUROCHEMISTRY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; REVIEW; SIGNAL TRANSDUCTION;

AFFECTIVE SYMPTOMS; ANIMALS; BIPOLAR DISORDER; BRAIN; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DOPAMINE; DOWN-REGULATION; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; REWARD; SEROTONIN; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33847767095     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.3.327     Document Type: Review

References (135)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depression. 2nd ed. Washington, DC: American Psychiatric Association; 2000.
2. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113:1237-1264.
3. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-522.
4. Randrup A, Munkvad I, Fog R, Gerlach J, Molander L, Kielberg B, Scheel-Kruger J. Mania, depression and brain dopamine. In: Essman WB, Valzelli S, eds. Current Developments in Psychopharmacology. Vol 2. New York, NY: Spectrum Publications; 1975:206-248.
5. Szabo ST, Gould TD, Manji HK. Neurotransmitters, receptors, signal transduction, and second messengers in psychiatric disorders. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Publishing Textbook of Psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press; 2004:3-52.
6. Sanchez-Gonzalez MA, Garcia-Cabezas MA, Rico B, Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci. 2005;25:6076-6083.
7. McClure SM, Berns G, Montague PR. Temporal prediction errors in a passive learning task activate human striatum. Neuron. 2003;38:339-346.
8. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724-763.
9. Matussek N, Ackenheil M, Hippius H, Muller F, Schroder HT, Schultes H, Wasilewski B. Effects of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res. 1980;2:25-36.
10. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189-225.
11. Jarvie KR, Caron MG. Heterogeneity of dopamine receptors. Adv Neurol. 1993;60:325-333.
12. Mansour A, Meador-Woodruff JH, Lopez JF, Watson SJ. Biochemical anatomy: insights into the cell biology and pharmacology of the dopamine and serotonin systems in the brain. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:55-74.
13. Clark D, White FJ. D1 dopamine receptor - the search for a function: a critical evaluation of the D1/D2 receptor classification and its functional implications. Synapse. 1987;1:347-388.
14. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18:2697-2708.
15. Redgrave P, Prescott TJ, Gurney K. Is the short-latency dopamine response too short to signal reward error? Trends Neurosci. 1999;22:146-151.
16. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80:1-27.
17. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-o- methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943-1961.
18. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol. 1996;298:27-30.
19. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003;1003:53-74.
20. Grace AA, Rosenkranz JA. Regulation of conditioned responses of basolateral amygdala neurons. Physiol Behav. 2002;77:489-493.
21. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12(suppl 3):S7-S14.
22. Spyraki C, Fibiger HC. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol. 1981;74:195-206.
23. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405:365-373.
24. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5:378-388.
25. Park SK, Nguyen MD, Fischer A, Luke MP, Affar el B, Dieffenbach PB, Tseng HC, Shi Y, Tsai LH. Par-4 links dopamine signaling and depression. Cell. 2005;122:275-287.
26. Salamone JD, Aberman JE, Sokolowski JD, Cousins MS. Nucleus accumbens dopamine and rate of responding: neurochemical and behavioral studies. Psychobiology. 1999;27:236-247.
27. Neill DB, Fenton H, Justice JB. Increase in accumbal dopaminergic transmission correlates with response cost not reward of hypothalamic stimulation. Behav Brain Res. 2002;137:129-138.
28. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol. 1995;281:255-261.
29. Keck ME, Welt T, Müller MB, Erhardt A, Ohl F, Toschi N, Holsboer F, Sillaber I. Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology. 2002;43:101-109.
30. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21:RC157.
31. Strafella AP, Paus T, Fraraccio M, Dagher A. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain. 2003;126:2609-2615.
32. D'Aquila PS, Collu M, Pani L, Gessa GL, Serra G. Antidepressant-like effect of selective D1 receptor agonists in the behavioural despair model animal model of depression. Eur J Pharmacol. 1994;262:107-111.
33. Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl). 1994;115:441-446.
34. Cheeta S, Broekkamp C, Willner P. Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology (Berl). 1994;116:523-528.
35. Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev. 1992;16:525-534.
36. Sherman AD, Sacquitine JL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav. 1982;16:449-454.
37. Anisman H, Irwin J, Sklar LS. Deficits of escape performance following catecholamine depletion: implications for behavioral deficits induced by uncontrollable stress. Psychopharmacology (Berl). 1979;64:163-170.
38. Anisman H, Remington G, Sklar LS. Effect of inescapable shock on subsequent escape performance: catecholamine and cholinergic mediation of response initiation and maintenance. Psychopharmacology (Berl). 1979;61:107-124.
39. Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, Drescher K, Fox GB, Decker MW, Rueter LE. Antidepressant-like effect of D2/3 receptor-, but not D4 receptor-activation in the rat forced swim test. Neuropsychopharmacology. 2005;30:1257-1268.
40. Borsini F, Meli A. The forced swimming test: its contribution to the understanding of the mechanisms of action of antidepressants. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford, England: Pergamon Press; 1990:63-76.
41. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552-1562.
42. Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, Laor N, Rauchverger B, Kreinin A, Poyurovsky M, Schneidman M, Modai I, Weizman R. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry. 1999;4:389-392.
43. Cravchik A, Goldman D. Neurochemical individuality: genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry. 2000;57:1105-1114.
44. Lopez Leon S, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. Biol Psychiatry. 2005;57:999-1003.
45. Dikeos DG, Papadimitriou GN, Avramopoulos D, Karadima G, Daskalopoulou EG, Souery D, Mendlewicz J, Vassilopoulos D, Stefanis CN. Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder. Psychiatr Genet. 1999;9:189-195.
46. Chiaroni P, Azorin JM, Dassa D, Henry JM, Giudicelli S, Malthiery Y, Planells R. Possible involvement of the dopamine D3 receptor locus in subtypes of bipolar affective disorder. Psychiatr Genet. 2000;10:43-49.
47. Cubells JF, Zabetian CP. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl). 2004;174:463-476.
48. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, Dahmen N. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5:49-53.
49. Volkow ND, Logan J, Fowler JS, Wang GJ, Gur RC, Wong C, Felder C, Gatley SJ, Ding YS, Hitzemann R, Pappas N. Association between age-related decline in dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry. 2000;157:75-80.
50. Banki CM. Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders. J Neurochem. 1977;28:255-257.
51. Bowers MB Jr, Heninger GR, Gerbode F. Cerebrospinal fluid 5-hydroxyindole-acetic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol. 1969;8:255-262.
52. Mendels J, Frazer A, Fitzgerald RG, Ramsey TA, Stokes JW. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science. 1972;175:1380-1382.
53. van Praag HM, Korf J. Retarded depression and the dopamine metabolism. Psychopharmacologia. 1971;19:199-203.
54. Nordin C, Siwers B, Bertilsson L. Bromocriptine treatment of depressive disorders: clinical and biochemical effects. Acta Psychiatr Scand. 1981;64:25-33.
55. Roy A, de Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-year follow-up study. Arch Gen Psychiatry. 1989;46:609-612.
56. van Praag HM, Korf J, Lakke JPWF, Schut T. Dopamine metabolism in depressions, psychoses and Parkinson's disease: the problem of the specificity of biological variables in behavior disorders. Psychol Med. 1975;5:138-146.
57. Goodwin FK, Post RM, Dunner DL, Gordon EK. Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique. Am J Psychiatry. 1973;130:73-79.
58. Jimerson DC. Role of dopamine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:505-511.
59. Vestergaard P, Sorensen T, Hoppe E, Rafaelsen OJ, Yates CM, Nicolaou N. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand. 1978;58:88-96.
60. Maas JW, Koslow SH, Katz MM, Bowden CL, Gibbons RL, Stokes PE, Robins E, Davis JM. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatry. 1984;141:1159-1171.
61. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE Jr. Effects of a dopamine agonist piribedil in depressed patients. Arch Gen Psychiatry. 1978;35:609-615.
62. van Scheyen JD, van Praag HM, Korf J. Controlled study comparing nomifensine and clomipramine in unipolar depression, using the probenecid technique. Br J Clin Pharmacol. 1977;4:179S-184S.
63. Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand. 1991;84:552-554.
64. Lambert G, Johansson M, Agren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness. Arch Gen Psychiatry. 2000;57:787-793.
65. Rocca P, De Leo C, Eva C, Marchiaro L, Milani AM, Musso R, Ravizza L, Zanalda E, Bogetto F. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26:1155-1160.
66. Cubells JF, Price LH, Meyers BS, Anderson GM, Zabetian CP, Alexopoulos GS, Nelson JC, Sanacora G, Kirwin P, Carpenter L, Malison RT, Gelernter J. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry. 2002;51:358-364.
67. McPherson H, Walsh A, Silverstone T. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord. 2003;76:121-125.
68. Ansseau M, von Frenckell R, Cerfontaine JL, Papart P, Franck G, Timsit-Berthier M, Geenen V, Legros JJ. Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry. 1988;153:65-71.
69. Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Pinto E, Reggers J, Ansseau M, Legros JJ. AVP- and OT-neurophysins response to apomorphine and clonidine in major depression. Psychoneuroendocrinology. 2005;30:839-845.
70. Monreal J, Duval F, Mokrani MC, Pinault G, Macher JP. Exploration de la fonction dopaminergique dans les depressions bipolares et unipolares. Ann Med Psychol (Paris). 2005;163:399-404.
71. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. Arch Neurol. 1996;53:175-179.
72. Bejjani BP, Damier P, Arnulf I, Thivard L, Bonnet AM, Dormont D, Cornu P, Pidoux B, Samson Y, Agid Y. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999;340:1476-1480.
73. Hasler G, Drevets WC, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29:1765-1781.
74. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry. 2002;59:409-416.
75. Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry. 2005;62:1228-1236.
76. Marinelli M, Piazza PV. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci. 2002;16:387-394.
77. Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand GS. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology. 2005;30:821-832.
78. Pruessner JC, Champagne F, Meaney MJ, Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care. J Neurosci. 2004;24:2825-2831.
79. McArthur S, McHale E, Dalley JW, Buckingham C, Gillies GE. Altered mesencephalic dopaminergic populations in adulthood as a consequence of brief perinatal glucocorticoid exposure. J Neuroendocrinol. 2005;17:475-482.
80. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am. 2000;23:11-25.
81. Pare CM, Yeung DP, Price K, Stacey RS. 5-Hydroxytryptamine, noradrenaline and dopamine in brainstem, hypothalamus and caudate nucleus of controls and patients committing suicide by coal gas poisoning. Lancet. 1969;2:133-135.
82. Moses SG, Robins E. Regional distribution of norepinephrine and dopamine in brains of depressive suicides and alcoholic suicides. Psychopharmacol Commun. 1975;1:327-337.
83. Bowden C, Cheetham SC, Lowther S, Katona CLE, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 1997;769:135-140.
84. Beskow J, Gotffries CG, Winblad B. Determination of monoamine and monoamine metabolites in the human brain: postmortem studies in a group of suicides and in a control group. Acta Psychiatr Scand. 1976;53:7-20.
85. Ohmori T, Arora RC, Meltzer HY. Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA and tryptophan in frontal cortex of suicide victims. Biol Psychiatry. 1992;32:57-71.
86. Crow TJ, Cross AJ, Cooper SJ, et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology. 1984;23:1561-1569 (12-B).
87. Engstrom G, Alling C, Blennow K, Regnell G, Tanskman-Bendz L. Reduced cerebrospinal HVA concentration and HVA/5-HIAA ratios in suicide attempters. Eur Neuropsychopharmacol. 1999;9:399-405.
88. Mann JJ, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry. 1997;41:162-171.
89. Bowden C, Theodorou AE, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 1997;752:227-233.
90. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nucleus in major depression: a postmortem study. Biol Psychiatry. 2002;52:740-748.
91. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by123I-2Beta-carbomethoxy-3Beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44:1090-1098.
92. D'Haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994;35:128-132.
93. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med. 1997;27:1247-1256.
94. Ebert D, Feistel H, Loew T, Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl). 1996;126:91-94.
95. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 1999;90:91-101.
96. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M. Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50:313-322.
97. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 2001;158:314-316.
98. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12:4121-4125.
99. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry. 2003;160:1836-1841.
100. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner HW. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5:251-260.
101. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry. 2000;157:457-459.
102. Gillings D, Grizzle J, Koch G, Rickels K, Amara I, Donelan M, Hardiman S, Nash R, Sollecito W, Stager W. Pooling 12 nomifensine studies for efficacy generalizability. J Clin Psychiatry. 1984;45:78-84.
103. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800-805.
104. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002;163:102-105.
105. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
106. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185-219.
107. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry. 1989;50:241-249.
108. Little KY. Amphetamine, but not methylphenidate, predicts antidepressant efficacy. J Clin Psychopharmacol. 1988;8:177-183.
109. Sitland-Marken PA, Wells BG, Froemming JH, Chu CC, Brown CS. Psychiatric applications of bromocriptine therapy. J Clin Psychiatry. 1990;51:68-82.
110. McGrath PJ, Quitkin FM, Klein DF. Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol. 1995;15:289-291.
111. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant- resistant depression. Biol Psychiatry. 1996;40:151-153.
112. Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, Kusumi I, Odagaki Y, Denda K, Ohmori T, Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord. 2000;61:127-132.
113. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull. 1993;29:207-211.
114. Mattes JA. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann Clin Psychiatry. 1997;9:87-88.
115. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156:798.
116. Perugi G, Toni C, Ruffolo G, Frare G, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34:137-141.
117. Sporn J, Ghaemi S, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12:137-140.
118. Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307-314.
119. DeBattista C, Solvason H, Heilig Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20:274-275.
120. Ostow M. Pramipexole for depression. Am J Psychiatry. 2002;159:320-321.
121. Black JK, Hershey T, Koller JM, Videen TO, Mintun MA, Price JL, Perlmutter JS. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A. 2002;99:17113-17118.
122. Corrigan MH, Denahan AQ, Wright E, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11:58-65.
123. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54-60.
124. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564-566.
125. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):13-21.
126. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):30-40.
127. McTavish SFB, Mannie ZN, Cowen PJ. Tyrosine depletion does not cause depressive relapse in antidepressant-treated patients. Psychopharmacology (Berl). 2004;175:124-126.
128. Roiser JP, McLean A, Ogilvie AD, Blackwell AD, Bamber DJ, Goodyer I, Jones PB, Sahakian BJ. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology. 2005;30:775-785.
129. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 1996;53:117-128.
130. Steinbush HWM. Serotonin-immunoreactive neurons and their projections in the CNS: classical transmitters and transmitter receptors in the CNS, part II. In: Bjorklun A, Hokfelt T, Kuhar MJ, eds. Handbook of Chemical Neuroanatomy. Vol 3. Amsterdam, the Netherlands: Elsevier; 1984:68-125.
131. Di Matteo V, De Blasi A, Di Giulio CD, Esposito E. Role of 5-HT2C receptors in control of central dopamine function. Trends Pharmacol Sci. 2001;22:229-232.
132. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci. 1999;249(suppl 4):90-98.
133. Gerson SC, Baldessarini R. Motor effects of serotonin in the central nervous system. Life Sci. 1980;27:1435-1451.
134. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rate ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther. 1994;271:83-90.
135. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol. 1995;116:1923-1931.